Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.00.

EPRX has been the topic of several analyst reports. Cantor Fitzgerald started coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, July 24th. They set an “overweight” rating and a $11.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Saturday, September 27th. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, August 20th. Finally, Canaccord Genuity Group began coverage on Eupraxia Pharmaceuticals in a research note on Monday, June 16th. They issued a “speculative buy” rating for the company.

Eupraxia Pharmaceuticals Stock Up 2.1%

NASDAQ:EPRX opened at $5.97 on Tuesday. The company has a market cap of $214.68 million, a P/E ratio of -7.02 and a beta of 1.51. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $7.19. The business has a 50 day moving average price of $5.48 and a two-hundred day moving average price of $4.61.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). As a group, analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Scotia Capital Inc. grew its position in shares of Eupraxia Pharmaceuticals by 11.6% in the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock valued at $5,072,000 after acquiring an additional 160,960 shares during the period. Royal Bank of Canada lifted its stake in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares during the last quarter. Ingalls & Snyder LLC bought a new position in Eupraxia Pharmaceuticals during the second quarter worth about $214,000. JPMorgan Chase & Co. increased its position in Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after buying an additional 16,017 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Eupraxia Pharmaceuticals during the second quarter worth approximately $61,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.